Table 1.

Clinical characteristics of the patient groups: with breast cancer and benign breast disease (control group)

Study group/subgroup	Number of patients
Breast cancer group	41
Menopausal status
pre-	6
post-	35
HRT	12
Histology type
ductal	37
lobular	3
other	1
Clinical stage:
a) Dcis	4
T1	25
T2	11
T4	1
b) N0 (lymph node negative)	29
N+ (lymph node positive)	12
Hormonal receptors status
ERα+, ERβ+, PgR+, HER-2–	12
ERα+, ERβ+, PgR+, HER-2+	7
ERα+, ERβ–, PgR+, HER-2–	12
ERα+, ERβ–, PgR+, HER-2+	4
ERα+, ERβ+, PgR–, HER-2–	1
ERα+, ERβ–, PgR–, HER-2+	2
ERα–, ERβ+, PgR–, HER-2+	1
ERα–, ERβ–, PgR–, HER-2–	1
ERα–, ERβ–, PgR–, HER-2+	1
Smoking history (positive)	9
Control group	28
Menopausal status
pre-	6
post-	22
HRT	10
Histology type
fibroadenoma	10
mastopatia fibrosa and cystica	16
adenosis sclerosans	2
hyperplasia ductalis	5
Smoking history (positive)	5

HRT – hormonal replacement therapy